These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 34257603

  • 1. Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
    Zhang Y, Qin Y, Xu H, Yao Q, Gao Y, Feng Y, Ren J.
    Pathol Oncol Res; 2021; 27():637745. PubMed ID: 34257603
    [Abstract] [Full Text] [Related]

  • 2. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Gadotti LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, Saddi R, Machado Alessi JV, de Abreu Testagrossa L, Katz A.
    Clin Lung Cancer; 2021 May; 22(3):e481-e486. PubMed ID: 32771343
    [No Abstract] [Full Text] [Related]

  • 3. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
    Dong W, Lei P, Liu X, Li Q, Cheng X.
    Front Immunol; 2021 May; 12():686057. PubMed ID: 34804000
    [Abstract] [Full Text] [Related]

  • 4. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J, Ohyanagi F, Amari H, Toda M, Tahara H, Yuzawa M, Maeda Y, Nomura M, Mizushina Y, Nagai Y, Ohta H, Yamaguchi Y.
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K, Katsurada N, Jimbo N, Tachihara M, Tamura D, Nakata K, Nagano T, Yamamoto M, Kamiryo H, Kobayashi K, Itoh T, Nishimura Y.
    Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
    [Abstract] [Full Text] [Related]

  • 6. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K, Naruse I, Shimizu K, Asao T.
    J Cancer Res Ther; 2020 May; 16(4):919-921. PubMed ID: 32930141
    [Abstract] [Full Text] [Related]

  • 7. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
    Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ.
    Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
    [Abstract] [Full Text] [Related]

  • 8. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS.
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [Abstract] [Full Text] [Related]

  • 9. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

  • 10. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
    Zhang Y, Fang H, Hong J, Wang X, Wang H, Pan G.
    Medicine (Baltimore); 2022 Aug 19; 101(33):e30094. PubMed ID: 35984185
    [Abstract] [Full Text] [Related]

  • 11. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA, Banyi N, Tucker T, Ionescu DN, Melosky B.
    Curr Oncol; 2022 Feb 03; 29(2):848-852. PubMed ID: 35200571
    [Abstract] [Full Text] [Related]

  • 12. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S, Shi C, Zhang H, Li J.
    Medicine (Baltimore); 2021 Dec 23; 100(51):e27999. PubMed ID: 34941039
    [Abstract] [Full Text] [Related]

  • 13. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Gonzalez-Mosquera LF, Rous FA, Rogers A, Smith N, Goyert G, Gadgeel S.
    Clin Lung Cancer; 2024 Mar 23; 25(2):e77-e80. PubMed ID: 38057186
    [Abstract] [Full Text] [Related]

  • 14. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T.
    BMC Cancer; 2017 Jul 06; 17(1):471. PubMed ID: 28683775
    [Abstract] [Full Text] [Related]

  • 15. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
    Anderson BE, Luczak TS, Ries LM, Hoefs GE, Silva-Benedict AC.
    J Oncol Pharm Pract; 2020 Dec 06; 26(8):2028-2030. PubMed ID: 32476587
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z, Wu R, Li C, Cheng K, Di Y, Lv T, Liu H, Song Y.
    Anticancer Drugs; 2023 Nov 01; 34(10):1069-1075. PubMed ID: 36688904
    [Abstract] [Full Text] [Related]

  • 17. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 01; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 18. Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Mattar MS, Chang J, Benayed R, Halpenny D, Powers A, Kleiner DE, Drilon A, Kris MG.
    Clin Lung Cancer; 2020 Jan 01; 21(1):e25-e29. PubMed ID: 31690489
    [No Abstract] [Full Text] [Related]

  • 19. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR, Loo C, Wegner EA, Nath CE, Lee S, Smith C, Lewis CR, Trahair TN, Anazodo AC.
    Pediatr Hematol Oncol; 2018 Jan 01; 35(7-8):415-421. PubMed ID: 30526220
    [Abstract] [Full Text] [Related]

  • 20. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A.
    Clin Lung Cancer; 2021 Jan 01; 22(1):e51-e53. PubMed ID: 32893122
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.